Clinical Trial Update: Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update for Beta-1,3/1,6-D-Glucan from Ganoderma Lucidum in ulcerative colitis; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Beta-1,3/1,6-D-Glucan Ganoderma Lucidum (Beta-1,3/1,6-D-Glucan)

Snippet

Sponsor: Fakultas Kedokteran Universitas Indonesia | Conditions: Ulcerative Colitis | Phase 2, Phase 3 | Status: UNKNOWN